Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391758 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL1928480 | 0.82 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL4028062 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL5384033 | 0.79 | LMNA (0.49) | ALDH1A1KMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL5402231 | 0.78 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1531280 | 0.78 | PTGDR2 (0.63) | ALDH1A1KMT2AMEN1TTRSMN1; SMN2 | |
| SCHEMBL1531330 | 0.78 | KMT2A (0.54) | ALDH1A1KMT2AMEN1TTRSMN1; SMN2 | |
| SCHEMBL18425852 | 0.77 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL4829743 | 0.77 | HTT (0.48) | ALDH1A1KMT2AMEN1TTRSMN1; SMN2 | |
| SCHEMBL5378784 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | disclosed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1436267-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033480-A1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | ADRB3, GPR3, ADRB1 | ALDH1A1 2468/4885KMT2A 3139/4885MEN1 1201/4885 |
| US-20060287321-A1 | Novel Lactam Derivatives | MRPL21, PEPD, STS | ALDH1A1 2328/4885KMT2A 3839/4885MEN1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.